Can lung cancer stem cells be targeted for therapies?

详细信息	查看全文 | 推荐本文 |

• 作者：Xiaodan Wu^a ; ^{physicianwuxd@126.com} ; Hong Chen^a ; ^{crazechh@gmail.com} ; Xiangdong Wang^a ; ^b ; ^{xiangdong.wang@telia.com}
• 关键词：Lung cancer ; Cancer stem cells ; Target ; Biomarkers ; Signal pathways ; Therapy
• 刊名：Cancer Treatment Reviews
• 出版年：2012
• 期刊代码：44_03057372
• 类别：med
• 出版时间：October, 2012
• 卷：38
• 期：6
• 页码：580-588
• 文件大小：747 K

摘要

Lung cancer is the leading cause of cancer death, with a poor prognosis. Lung cancer stem cells (CSCs) are proposed as one of therapeutic targets for lung cancer. It is important to understand the exact role of lung CSC subpopulations in tumor initiation, recurrence, drug resistance and metastasis and explore biomarkers, signaling pathways and differentiation regulation specific to lung CSCs. Numerous measures targeting lung CSCs, e.g. genomics, proteomics and bioinformatics, have been used to investigate molecular mechanisms, eradicate cancer cells, and improve patient outcome. The present review overviewed the biological functions, biomarkers, signal pathways, differentiation regulation, genomics and proteomics, targeting roles of lung CSCs and related information on other CSCs as references. There are still a number of challenges to translate the research and understanding of lung CSCs to clinical applications and therapies, identify lung CSCs-specific and dynamic network biomarkers, study lung CSCs isolated from human samples, and clarify the source of lung CSCs. It is necessary to design effective therapies to target CSC biomarkers and signaling pathways, reverse drug resistance and induce differentiation of lung CSCs. Thus, lung CSCs as one of therapeutic target candidates for lung cancer need global forces and databases to integrate the genes, proteins, receptors, signal pathways and functions with clinical informatics and phenotypes together.